Handel ACADIA Pharmaceuticals Inc - ACAD CFD

Warunki handlu

• Typ:
  CFD

  

  Knock-out

  
• Spread: 0.11
• Korekta finansowania pozycji długiej overnight: -0.02151%
• Korekta finansowania pozycji krótkiej overnight: -0.00071%
• Korekta finansowania overnight: 21:00 (UTC)
• Waluta: USD
• Min. wielkość handlu: 0.1
• Depozyt zabezpieczający: 50.00%
• Giełda papierów wartościowych: United States of America
• Prowizja od transakcji: 0%
• Opłata za gwarantowany stop: 1%

Najważniejsze statystyki

• Poprz. zamknięcie: 21.4
• Otwarcie: 21.61
• Zmiana 1 r.: 48.93%
• Zakres dzienny: 21.44 - 21.98

Handel ACADIA Pharmaceuticals Inc - ACAD CFD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson''s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.